Adalimumab

General description

INN	Adalimumab
ATC codes	L04AB04
Medicine type	Biological agent
EML status history	First added in 2019 (TRS 1021) for Rheumatoid arthritis Added in 2019 (TRS 1021) for Axial spondyloarthritis Added in 2019 (TRS 1021) for Juvenile idiopathic arthritis Added in 2019 (TRS 1021) for Crohn disease site Added in 2025 (TRS 1064) for Psoriasis of unspecified type
Wikipedia	Adalimumab
DrugBank	Adalimumab

Recommendations

Section Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

Rheumatoid arthritis | Axial spondyloarthritis | Crohn disease site

Section Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

Juvenile idiopathic arthritis

Section Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.

Indications

Psoriasis of unspecified type